Suppr超能文献

美国高危患者的血管内主动脉瘤修复术及院内死亡率

Endovascular aortic aneurysm repair in patients with the highest risk and in-hospital mortality in the United States.

作者信息

Timaran Carlos H, Veith Frank J, Rosero Eric B, Modrall J Gregory, Arko Frank R, Clagett G Patrick, Valentine R James

机构信息

Division of Vascular and Endovascular Surgery, Department of Surgery, University of Texas Southwestern Medical Center, 5909 Harry Hines Boulevard, Dallas, TX 75390-9157, USA.

出版信息

Arch Surg. 2007 Jun;142(6):520-4; discussion 524-5. doi: 10.1001/archsurg.142.6.520.

Abstract

BACKGROUND

A randomized clinical trial from the United Kingdom (EVAR trial 2) comparing endovascular aortic aneurysm repair (EVAR) with no intervention found no advantage for EVAR in patients with high risk. This finding was predominantly caused by the substantial in-hospital mortality after EVAR (9%).

HYPOTHESIS

The nationwide in-hospital mortality for patients with the highest risk undergoing EVAR in the United States is lower than that reported in EVAR trial 2.

DESIGN

Population-based, cross-sectional study.

SETTING

The 2001-2004 Nationwide Inpatient Sample.

PATIENTS AND METHODS

The Nationwide Inpatient Sample identified EVAR procedures for nonruptured abdominal aortic aneurysms. Risk stratification was based on comorbidities and the Charlson comorbidity index, a validated predictor of in-hospital mortality after abdominal aortic aneurysms repairs. Weighted univariate and logistic regression analyses were used to determine the association between comorbidity measures and risk-adjusted in-hospital mortality.

RESULTS

During the 4-year period, 65 502 EVARs were performed with an in-hospital mortality of 2.2%. Risk-adjusted in-hospital mortality rates ranged from 1.2% to 3.7%. Stratified analyses, including only elective EVAR procedures, revealed that in-hospital mortality was significantly higher in patients with the most severe comorbidities (1.7%) vs those with lower comorbidity (0.4%; P<.001). Patients with high risk had only a 1.6-fold increased risk of adjusted in-hospital mortality (odds ratio, 1.6; 95% confidence interval, 1.2-2.2) compared with patients with low risk.

CONCLUSIONS

The EVAR procedure is currently being performed in the United States with low in-hospital mortality, even in patients with the highest risk. Therefore, EVAR should not be denied to high-risk patients with abdominal aortic aneurysms in the United States on the basis of the level I evidence from the United Kingdom study.

摘要

背景

英国的一项随机临床试验(EVAR试验2)比较了血管内主动脉瘤修复术(EVAR)与不进行干预,结果发现对于高危患者,EVAR并无优势。这一发现主要是由于EVAR术后较高的住院死亡率(9%)所致。

假设

在美国,接受EVAR的最高危患者的全国住院死亡率低于EVAR试验2中所报告的死亡率。

设计

基于人群的横断面研究。

设置

2001 - 2004年全国住院患者样本。

患者与方法

全国住院患者样本确定了非破裂性腹主动脉瘤的EVAR手术。风险分层基于合并症和查尔森合并症指数,这是腹主动脉瘤修复术后住院死亡率的有效预测指标。采用加权单因素和逻辑回归分析来确定合并症指标与风险调整后的住院死亡率之间的关联。

结果

在4年期间,共进行了65502例EVAR手术,住院死亡率为2.2%。风险调整后的住院死亡率在1.2%至3.7%之间。仅包括择期EVAR手术的分层分析显示,合并症最严重的患者住院死亡率(1.7%)显著高于合并症较轻的患者(0.4%;P<0.001)。与低危患者相比,高危患者调整后的住院死亡风险仅增加了1.6倍(比值比,1.6;95%置信区间,1.2 - 2.2)。

结论

目前在美国进行EVAR手术的住院死亡率较低,即使是最高危的患者。因此,基于英国研究的一级证据,在美国不应因腹主动脉瘤而拒绝为高危患者进行EVAR手术。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验